Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATTO-3712 · 1 trial · 4 indications
The primary analysis will describe the incidence of AEs and laboratory abnormalities. AEs will be coded according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA, version 28.0 or the current version). Their severity will be graded using the NCI CTCAE v5.0 or the current version.
Clinical laboratory parameters (hematologic and blood chemistry) will be summarized by visit
ECG findings (including QT abnormalities) will be summarized by visit.
Vital signs (systolic and diastolic blood pressure, temperature, heart rate) will be summarized by visit.
| Arm | Type | Description |
|---|---|---|
| ATTO-3712 single dose IV | EXPERIMENTAL | ATTO-3712 Dose level cohorts receiving a single dose IV |
| Placebo single dose IV | PLACEBO_COMPARATOR | Placebo preparation to match Experimental Arm with single dose IV |
| ATTO-3712 single dose SC | EXPERIMENTAL | ATTO-3712 dose level cohorts receiving a single dose SC |
| Placebo single dose SC | PLACEBO_COMPARATOR | Placebo preparation to match Experimental Arm with single dose SC |
| ATTO-3712 multiple dose SC | EXPERIMENTAL | ATTO-3712 administered to dose level cohorts in multiple SC doses |
| Placebo multiple dose SC | PLACEBO_COMPARATOR | Placebo preparation to match Experimental Arm administered in multiple SC doses |
| Name | Type | Description |
|---|---|---|
| ATTO-3712 | DRUG | ATTO-3712 |
| Placebo | DRUG | Placebo preparation to match ATTO-3712 dose |
Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria: * Any sex or gender who is 18 to 65 years old, inclusive, at Screening. * Body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 35 kg/m2 * Considered in good general health based on medical history, physical exam, 12-lead ECG,...
Top 20 of 26 competitors
ATTO-3712 is an investigational small molecule being developed by Alamar Biosciences, Inc. for atopic dermatitis, also known as atopic eczema. It has been studied in a Phase 1 clinical trial that enrolled 48 participants, including healthy volunteers and patients with atopic dermatitis. It is not yet approved for any use.
ATTO-3712 is being evaluated as a treatment for atopic dermatitis, a chronic inflammatory skin condition also called atopic eczema. The Phase 1 trial that studied it included patients with atopic dermatitis alongside healthy volunteers. Because the program is still in Phase 1, ATTO-3712 is investigational and has no approved indication.
ATTO-3712 is being developed by Alamar Biosciences, Inc., which trades under the ticker ALMR. The company is the sponsor of the Phase 1 trial evaluating the compound in healthy volunteers and patients with atopic dermatitis.
ATTO-3712 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The study was randomized, double-blind, and placebo-controlled, enrolling 48 participants. ATTO-3712 has not been approved by the FDA and remains an investigational drug.
ATTO-3712 has been studied in one Phase 1 trial, NCT07205081, titled Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis. The trial is completed, enrolled 48 participants, and ran in the United States, Canada, and New Zealand. It included adults 18 years and older of all sexes.
The ATTO-3712 Phase 1 trial, NCT07205081, was a randomized, double-blind, placebo-controlled study of safety, tolerability, and pharmacokinetics. It enrolled 48 participants, including healthy volunteers and patients with atopic dermatitis, across sites in the United States, Canada, and New Zealand. Participants were 18 years or older, and the trial is now completed.